A substantial advancement in diabetes care is emerging with the approval of tirzepatide at a dosage of 45mg. This updated version builds upon the existing success of tirzepatide, a dual GIP and GLP-1 agonist, and https://socialstrategie.com/story7063346/groundbreaking-approach-tirzepatide-dose-for-blood-sugar-management